human growth hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-19. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
== History == This methodology was first published in 1996 by a lab at Stanford University. Previous attempts to quantify antigen-specific T-cells involved the less accurate limiting dilution assay, which estimates numbers of T-cells at 50-500 times below their actual levels. Stains using soluble MHC monomers were also unsuccessful due to the low binding affinity of T-cell receptors and MHC-peptide monomers. MHC tetramers can bind to more than one receptor on the target T-cell, resulting in an increased total binding strength and lower dissociation rates.
the post void residual volume (PVR, ml) was significantly decreased the maximum urinary flow (Qmax, ml/s) was increased the voiding time (VT, s) was decreased This urodynamic profile is related to a lower risk of urologic complications, such as cystitis and bladder stones.
== Early life and education == Shaw was born in South Boston, and also grew up in Brookline, Massachusetts. Her mother was from South Boston. Shaw's parents divorced when she was four years old. She grew up in a single-mother home with an older half-brother, who owns a bar in Boston. Shaw attended Michael Driscoll School and Brookline High School. At Michael Driscoll, Shaw played full court streetball at a nearby neighborhood park. Shaw said that basketball was a constant of her childhood, and she incorporated it into the pilot and third episode of SMILF. After receiving a scholarship in her junior year, Shaw transferred to the private school Milton Academy in Milton, Massachusetts, where she graduated in 2000. In 2007, she graduated from Barnard College with a degree in literature.
Sac6 Sla1p Srv2 (CAP) S-adenosyl-L-homocysteine hydrolase, (SAHH) Sla2p Synaptopodin Scinderin (adseverin) Synapsins Scruin Spectrin Severin Spectraplakins SVSII Shot (Short stop) Spire Shroom Smitin (Smooth Musc.Titin) Supervillin SipA Smoothelin Sucrose synthetase SipC Sra-1 Spinophilin Ssk2p Swinholide Talin protein Toxophilin Twinfilin Tau Trabeculin Twinstar TCP-1 Transgelin Transgelin 2 Transgelin 3 Tensin Tropomodulin Thymosin Tropomyosin Titin Troponin TOR2 Tubulin bIV Ulapualide Utrophin Unc-87 Unc-60 (ADF/cofilins) VASP Vav Verprolin VDAC Vibrio cholerae RTX toxin Villin Vinculin Vitamin D-binding protein WIP WASp Y-box proteins YpkA (YopO) Zipper protein Zo-1 Zyxin The Encyclopaedia of Actin-Binding Proteins (and Drugs)– alphabetical list, sourced profile for each Maciver, Sutherland (ed.). "The Encyclopaedia of Actin-Binding Proteins (and Drugs)". Maciver Lab Web Page (online ed.). School of Biomedical Sciences, University of Edinburgh. Archived from the original on 2005-11-24. Actin-Binding+Proteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Greater emphasis on risk management Introduces “Special Requirements” Introduces “Critical Items” Measure: Requirements conformance Measure: Delivery performance Adopt proven product development processes Eliminate “recurring corrective actions” AS9100 Revision C was released in January, 2009, with considerable delay in application of the new version in audits, largely due to the delay in the release of AS9101 Revision D and auditor training to the increased auditing rigor of that update. AS9100 Revision D (2016), Quality Management System – Requirements for Aviation, Space and Defense Organizations The update of AS9100 from revision C to D includes the full text of ISO 9001:2015. In addition to aligning the structure of the aviation, space and defense requirements to the new structure of ISO 9001:2015, the following key changes were implemented:
Sources: en.wikipedia.org
Thirty-four isotopes of actinium and eight excited isomeric states of some of its nuclides are known, ranging in mass number from 203 to 236. Three isotopes, 225Ac, 227Ac and 228Ac, were found in nature and the others were produced in the laboratory; only the three natural isotopes are used in applications. Actinium-225 is a member of the radioactive neptunium series; it was first discovered in 1947 as a decay product of uranium-233 and it is an α-emitter with a half-life of 10 days. Actinium-225 is less available than actinium-228, but is more promising in radiotracer applications. Actinium-227 (half-life 21.77 years) occurs in all uranium ores, but in small quantities. One gram of uranium (in radioactive equilibrium) contains only 2×10−10 gram of 227Ac. Actinium-228 is a member of the radioactive thorium series formed by the decay of 228Ra; it is a β− emitter with a half-life of 6.15 hours. In one tonne of thorium there is 5×10−8 gram of 228Ac. It was discovered by Otto Hahn in 1906. There are 32 known isotopes of thorium ranging in mass number from 207 to 238. Of these, the longest-lived is 232Th, whose half-life of 1.4×1010 years means that it still exists in nature as a primordial nuclide. The next longest-lived is 230Th, an intermediate decay product of 238U with a half-life of 75,400 years. Several other thorium isotopes have half-lives over a day; all of these are also transient in the decay chains of 232Th, 235U, and 238U. Twenty-nine isotopes of protactinium are known with mass numbers 211–239 as well as three excited isomeric states.
=== Oxidation === The oxidation of isatin using hydrogen peroxide (Baeyer–Villiger oxidation) or chromic anhydride yields isatoic anhydride, a compound widely used either in herbicide products and in medicinal chemistry. The use of peroxydisulfuric acid gives rise to 1,4‑benzoxazine compounds.
In symbolic terms, he was seen as signifying parliamentary control over the Army. Issues of strategic policy during wartime were managed by the Northern and Southern Departments (the predecessors of today's Foreign Office and Home Office). From 1704 to 1855 the post of Secretary remained occupied by a minister of the second rank (although he was occasionally part of the Cabinet after 1794). Many of his responsibilities were transferred to the Secretary of State for War after the creation of that more senior post in 1794 (though the latter was also responsible for Britain's colonies from 1801, and renamed Secretary of State for War and the Colonies, an arrangement which only ceased with the establishment of the Colonial Office in 1854). From 1824 the British Empire (excepting India, which was administered separately by the East India Company and then the India Office) was divided by the War and Colonial Office into the following administrative departments: North America
When a surface is immersed in a solution containing electrolytes, it develops a net surface charge. This is often because of ionic adsorption. Aqueous solutions universally contain positive and negative ions (cations and anions, respectively), which interact with partial charges on the surface, adsorbing to and thus ionizing the surface and creating a net surface charge. This net charge results in a surface potential [L], which causes the surface to be surrounded by a cloud of counter-ions, which extends from the surface into the solution, and also generally results in repulsion between particles. The larger the partial charges in the material, the more ions are adsorbed to the surface, and the larger the cloud of counter-ions. A solution with a higher concentration of electrolytes also increases the size of the counter-ion cloud. This ion/counterion layer is known as the electric double layer. A solution's pH can also greatly affect surface charge because functional groups present on the surface of particles can often contain oxygen or nitrogen, two atoms which can be protonated or deprotonated to become charged. Thus, as the concentration of hydrogen ions changes, so does the surface charge of the particles. At a certain pH, the average surface charge will be equal to zero; this is known as the point of zero charge (PZC). A list of common substances and their associated PZCs is shown to the right.
Moscow is the capital and largest city of Russia, situated on the Moskva River in Central Russia. The city has a population estimated at more than 13 million residents within city limits, more than 19.1 million residents in the urban area, and more than 21.5 million residents in the metropolitan area. The city covers an area of 2,511 square kilometers (970 sq mi); the urban area covers 5,891 square kilometers (2,275 sq mi); and the metropolitan area covers more than 26,000 square kilometers (10,000 sq mi). Moscow is among the world's largest cities: the most populous city entirely in Europe, the largest urban and metropolitan areas in Europe, and the largest city by land area on the European continent. First documented in 1147, Moscow became the capital of the Grand Principality of Moscow, which led the unification of Russian lands in the 15th century and became the center of a unified state. Following the proclamation of the Tsardom of Russia in 1547, Moscow remained the country's political and economic center for most of its history. During the reign of Peter the Great, the Russian capital was moved to the newly founded city of Saint Petersburg in 1712, leading to a decline in Moscow's importance throughout the imperial period. Following the Russian Revolution and the establishment of the Russian Soviet Federative Socialist Republic (Russian SFSR), the capital was moved back to Moscow in 1918. The city later became the political center of the Soviet Union and experienced significant population growth throughout the Soviet period.
Sources: en.wikipedia.org
=== Sources === Ammirati JF, Traquair JA, Horgen PA (1985). Poisonous Mushrooms of Canada: Including other Inedible Fungi. Markham, Ontario: Fitzhenry & Whiteside in cooperation with Agriculture Canada and the Canadian Government Publishing Centre, Supply and Services Canada. ISBN 978-0-88902-977-4. Hall IR, Stephenson SL, Buchanan PK, Yun W, Cole AL (2003). Edible and Poisonous Mushrooms of the World. Portland, Oregon: Timber Press. ISBN 978-0-88192-586-9. Stuntz DE, Largent DL, Thiers HD, Johnson DJ, Watling R (1978). How to Identify Mushrooms to Genus I. Eureka, California: Mad River Press. ISBN 978-0-916422-00-4. Jaini, Padmanabh S. (1998) [1979], The Jain Path of Purification, Delhi: Motilal Banarsidass, ISBN 978-81-208-1578-0 Laidlaw, James (1995), Riches and Renunciation. Religion, economy, and society among the Jains, Oxford, ISBN 978-0198280316
The constriction toward the tip of the Pasteur pipettes may be plugged with a bit of tissue paper or cotton wool to filter off solids from small amounts of liquids. The bulb can be attached and squeezed to help viscous solutions filter more rapidly. With a bit of skill, Pasteur pipettes may also be used for microscale column chromatography. With appropriately fine silica gel, the bulb may be squeezed for microscale flash column chromatography.
== Interactions == Extracellular interaction with a tripartite receptor composed of gp130, WSX1, and CNTFR, as well as interaction with the formyl peptide receptor 2 (formylpeptide-like-1 receptor) have been published. Intracellular interaction with BAX, tBID, IGFBP3, and TRIM11 may also be required for the effects of humanin.
Ketoconazole, sold under the brand name Nizoral, among others, is an antiandrogen, antifungal, and antiglucocorticoid medication used to treat a number of fungal infections. Applied to the skin it is used for fungal skin infections such as tinea, cutaneous candidiasis, pityriasis versicolor, dandruff, and seborrheic dermatitis. Taken by mouth it is a less preferred option and recommended for only severe infections when other agents cannot be used. Other uses include treatment of excessive male-patterned hair growth in women and Cushing's syndrome. Common side effects when applied to the skin include redness. Common side effects when taken by mouth include nausea, headache, and liver problems. Liver problems may result in death or the need for a liver transplantation. Other severe side effects when taken orally include QT prolongation, adrenocortical insufficiency, and anaphylaxis. It is an imidazole and works by hindering the production of ergosterol required for the fungal cell membrane, thereby slowing growth. Ketoconazole was patented in 1977 by Belgian pharmaceutical company Janssen, and came into medical use in 1981. It is available as a generic medication and formulations that are applied to the skin are over the counter in the United Kingdom. In 2023, it was the 140th most commonly prescribed medication in the United States, with more than 3 million prescriptions. The formulation that is taken by mouth was withdrawn in the European Union and in Australia in 2013, and in China in 2015. In addition, its use was restricted in the United States and Canada in 2013.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.